SEC Filing Summary: TransBiotec, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by TransBiotec, Inc., a Delaware corporation, with a report date of April 1, 2016. The filing discloses a corporate action regarding a proposed capital raise. Note: The request metadata references "SOBR Safe, Inc.," but the filing text explicitly identifies the registrant as TransBiotec, Inc.
Key Financial Metrics and Capital Structure
The filing does not report historical revenue, profit, cash flow, or existing debt levels. Instead, it outlines the terms of a proposed financing:
- Target Raise: Up to $3,000,000.
- Minimum Threshold: $200,000 must be raised to receive proceeds.
- Instrument: Unsecured convertible debentures.
- Interest Rate: 12% per annum.
- Maturity: 36 months after issuance.
- Conversion Terms: Convertible 12 months after issuance at a 35% discount to the average closing price of common stock for the 15 trading days prior to conversion.
- Placement Fees: Up to 8% of the total amount raised.
Material Changes
The Board of Directors voted on April 1, 2016, to initiate the Offering under Rule 506(c) of Regulation D. This represents a material change in the company's capitalization strategy, moving from no active offering to a "best efforts" private placement available only to accredited investors.
Outlook, Risks, and Contingencies
Outlook: The company intends to raise capital to support operations, subject to the minimum funding threshold of $200,000. The offering is conducted on a "best efforts" basis, meaning there is no guarantee the full $3,000,000 will be raised.
Risks and Contingencies:
- Dilution Risk: The 35% discount rate on conversion could significantly dilute existing shareholders upon conversion.
- Cost of Capital: The 12% interest rate represents a high cost of debt.
- Execution Risk: If the minimum $200,000 is not raised, the company will receive no proceeds from the offering.
- Liquidity: The debentures are unsecured, increasing risk for investors and potentially limiting future borrowing capacity.
Investor Verification Checklist
- Verify the current cash position of TransBiotec, Inc. to assess the urgency of this capital raise.
- Confirm whether the minimum $200,000 threshold has been met and if the offering is currently active.
- Review the company's existing debt load to understand the impact of adding 12% interest-bearing debt.
- Assess the potential dilution impact of the 35% conversion discount on current share price.
- Check for any subsequent filings (e.g., 8-K updates) regarding the actual amount raised.